• 0.75mg, 1.5mg, 3mg and 4.5mg prefilled syringes
  
  • Approved for use in patients who require once-weekly GLP-1 receptor agonist therapy. 
  • This has replaced once-weekly exenatide. Existing patients can continue to receive exenatide until reviewed by a specialist

5 microgram and 10 microgram per dose are prefilled injection pens containing a 250microgram/ml solution for subcutaneous injection.

Only approved for use in accordance with NICE guidance. Treatment must be initiated by a consultant diabetologist and use is limited to overweight patients with type 2 diabetes in line with NICE guidelines.

0.25mg/0.19mL, 0.5mg/0.37mL and 1mg/0.7mL solution for injection pre-filled pen (Ozempic^®) 

• Approved for the treatment of type 2 diabetes in patients who require an intensification in treatment

1.5mg, 4mg, 9mg tablets (Rybelsus^®) 

• New formulation with increased bioavailability. New patients should be started on the new formulation. 
• See information for healthcare professionals and information for patients
• Approved as an option for patients with type 2 diabetes mellitus who require intensification of treatment, if use of a glucagon-like peptide 1 receptor agonist (GLP1RA) is clinically appropriate, in line with licensing and relevant guidance, and if an oral option is preferred.

0.25mg/0.37ml, 0.5mg/0.37ml, 1mg/0.75ml, 1.7mg/0.75ml & 2.4mg/0.75ml solution for injection pre-filled pens (Wegovy^®) 

• Approved for managing overweight and obesity in line with NICE guidance within a specialist weight management service (including but not limited to tiers 3 and 4)
• Also available via NHSE pilot sites involving primary care.
• 7.2mg dose should not be prescribed until NICE guidance is available

2.4ml pre-filled pens (1 pen = 4 doses): 2.5mg/0.6ml, 5mg/0.6ml, 7.5mg/0.6ml, 10mg/0.6ml, 12.5mg/0.6ml & 15mg/0.6ml KwikPens^®

Approved for

• treating type 2 diabetes in line with NICE
• as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults in line with NHSE Interim commissioning guidance and NENC ICB HWTO Prioritisation Policy. Should only be prescribed in primary care for overweight and obesity within commissioned services and with wrap around care.

• Biosimilars available. These biosimilars should be prescribed by brand name as licensed indications differ.
•  
  
  • Approved for the treatment of type 2 diabetes mellitus in accordance with NICE guidance   

•  
  
  • Approved as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults in line with NICE and providing: 
    
    • it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service; and
  • the company provides it according to the commercial arrangement